The establishment of clinical susceptibility breakpoints (susceptible, intermediate and resistant) mainly relies on the in vitro activity of an antibiotic against a sizeable bacterial sample, combined with some pharmacological parameters (e.g., blood and infection site concentrations of the antimicrobial, among others).
![ja rule body 2015 ja rule body 2015](https://i.ytimg.com/vi/W0dmvLjVypw/maxresdefault.jpg)
Second, it is important to recognize that the concept of antimicrobial resistance/susceptibility in clinical practice is a relative phenomenon with many layers of complexity. As it will be discussed later in the chapter, the development of acquired resistance can be the result of mutations in chromosomal genes or due to the acquisition of external genetic determinants of resistance, likely obtained from intrinsically resistant organisms present in the environment. Rather, in clinical settings, we are typically referring to the expression of “acquired resistance” in a bacterial population that was originally susceptible to the antimicrobial compound. However, when discussing the antimicrobial resistance conundrum, bacteria harboring intrinsic determinants of resistance are not the main focus of the problem. Thus, these organisms are often considered to be “intrinsically” resistant to one or more antimicrobials. Most antimicrobial compounds are naturally-produced molecules, and, as such, co-resident bacteria have evolved mechanisms to overcome their action in order to survive. First, antimicrobial resistance is ancient and it is the expected result of the interaction of many organisms with their environment. In order to understand the problem of antimicrobial resistance, it is useful to discuss some relevant concepts. This situation is worsened by a paucity of a robust antibiotic pipeline, resulting in the emergence of infections that are almost untreatable and leaving clinicians with no reliable alternatives to treat infected patients. Moreover, according to a recent report, antibiotic resistance is estimated to cause around 300 million premature deaths by 2050, with a loss of up to $100 trillion (£64 trillion) to the global economy ( 6). The Centers for Disease Control and Prevention conservatively estimates that at least 23,000 people die annually in the USA as a result of an infection with an antibiotic-resistant organism ( 5).
![ja rule body 2015 ja rule body 2015](https://townsquare.media/site/812/files/2020/06/50-cent-clowns-french-montana.jpg)
Infections caused by multidrug-resistant (MDR) organisms are associated with increased mortality compared to those caused by susceptible bacteria and they carry an important economic burden, estimated at over 20 billion dollars per year in the US only ( 2, 3, 4). In fact, the World Health Organization has named antibiotic resistance as one of the three most important public health threats of the 21 st century ( 1). Unfortunately, the marked increase in antimicrobial resistance among common bacterial pathogens is now threatening this therapeutic accomplishment, jeopardizing the successful outcomes of critically ill patients. Indeed, antibiotics have become one of the most important medical interventions needed for the development of complex medical approaches such as cutting edge surgical procedures, solid organ transplantation and management of patients with cancer, among others. The discovery, commercialization and routine administration of antimicrobial compounds to treat infections revolutionized modern medicine and changed the therapeutic paradigm. In this chapter, we will describe in detail the major mechanisms of antibiotic resistance encountered in clinical practice providing specific examples in relevant bacterial pathogens. Therefore, understanding the biochemical and genetic basis of resistance is of paramount importance to design strategies to curtail the emergence and spread of resistance and devise innovative therapeutic approaches against multidrug-resistant organisms.
![ja rule body 2015 ja rule body 2015](https://i.ytimg.com/vi/qxKalQb5i-I/hqdefault.jpg)
“Survival of the fittest” is a consequence of an immense genetic plasticity of bacterial pathogens that trigger specific responses that result in mutational adaptations, acquisition of genetic material or alteration of gene expression producing resistance to virtually all antibiotics currently available in clinical practice. The bacterial response to the antibiotic “attack” is the prime example of bacterial adaptation and the pinnacle of evolution. Multidrug-resistant organisms have emerged not only in the hospital environment but are now often identified in community settings, suggesting that reservoirs of antibiotic-resistant bacteria are present outside the hospital. Emergence of resistance among the most important bacterial pathogens is recognized as a major public health threat affecting humans worldwide.